CW November 2002
Volume 11Issue Number 11 November 2002 ISSN 10593802 GOG to Conduct Phase III of XYOTAX in Ovarian CancerGynecologic Oncology Group (GOG) announced this month that GOG will conduct a phase III trial of XYOTAX in front-line treatment of ovarian cancer, The trial is expected to begin in 2003 and to enroll approximately 1,000 patients for a period of over 12 months.
Go to Previous Page Go to Next Page Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW November 2002Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
